Amphastar Pharmaceuticals (AMPH) Stock Price
Amphastar Pharmaceuticals Price
Revenue has compounded at 10.4% per year over the past 16 years to 719.89 M USD. Earnings per share have grown at 18.3% per year over the last 14 years. Amphastar Pharmaceuticals's net margin stands at 13.6%, broadly stable from 14.2% several years earlier. Analysts set a median price target of 21.50 USD, implying 20.3% below the current price. Of 12 analysts, 0 rate the stock a buy — an overall Hold consensus.
Amphastar Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Amphastar Pharmaceuticals business model & stock analysis
Frequently asked questions about Amphastar Pharmaceuticals
The business model of Amphastar Pharmaceuticals Inc involves researching, developing, manufacturing, and marketing generic and specialty injectable and inhalation products. As a leading pharmaceutical company, Amphastar focuses on leveraging its extensive expertise in the development of complex generic and innovative specialty pharmaceuticals. By offering a diverse range of products to address critical medical needs, Amphastar aims to improve patient outcomes and enhance access to cost-effective medications. Furthermore, the company actively seeks partnerships and collaborations to expand its product portfolio and enhance its market presence. Amphastar Pharmaceuticals Inc remains committed to providing high-quality pharmaceuticals and driving healthcare advancements.
Amphastar Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Amphastar Pharmaceuticals Inc in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., and Novartis International AG.
Amphastar Pharmaceuticals Inc, a leading pharmaceutical company, has a rich history and background in the healthcare industry. Established in 1996, Amphastar has grown to become a renowned provider of generic and biosimilar products worldwide. The company specializes in developing, manufacturing, and marketing a wide range of quality and affordable pharmaceuticals, including injectables, inhalation products, and intranasal sprays. Amphastar has achieved significant milestones over the years, including FDA approvals for various products and strategic partnerships with global pharmaceutical companies. Committed to enhancing patient care and achieving business excellence, Amphastar Pharmaceuticals Inc continues to shape the future of the healthcare industry through innovation and dedication.
Amphastar Pharmaceuticals Inc has achieved significant milestones throughout its history. Some of these achievements include the successful development and commercialization of various generic and branded pharmaceutical products. The company has also received numerous regulatory approvals, expanded its product portfolio, and established strategic partnerships to enhance its market presence. With a strong focus on research and innovation, Amphastar Pharmaceuticals Inc continues to deliver high-quality and affordable medications to meet the needs of patients worldwide.
Amphastar Pharmaceuticals Inc is primarily present in the United States.
Amphastar Pharmaceuticals Inc represents values of integrity, innovation, and commitment to patient care. As a leading pharmaceutical company, their corporate philosophy focuses on delivering high-quality and affordable medicines to improve health outcomes worldwide. Amphastar Pharmaceuticals Inc is dedicated to advancing medical knowledge and developing innovative therapies that address unmet medical needs. With their patient-centric approach, they strive to enhance access to life-saving medications, ensuring the well-being of individuals and communities. Their commitment to ethical practices and social responsibility is reflected in their extensive range of high-value generic and proprietary products. Amphastar Pharmaceuticals Inc's dedication to excellence and patient welfare sets them apart in the pharmaceutical industry.
Analysts currently set an average price target of 21.25 USD for the Amphastar Pharmaceuticals stock (median: 21.50 USD), implying -21.3 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Amphastar Pharmaceuticals stock: 0 recommend buying, 8 holding and 4 selling. For 2026, analysts expect Amphastar Pharmaceuticals to generate revenue of 747.81 M USD and earnings per share of 3.04 USD.
Converted at the current exchange rate, the Amphastar Pharmaceuticals share trades at 24.07 EUR (26.99 USD).
The Amphastar Pharmaceuticals share (AMPH) is listed on 4 stock exchanges, including: NASDAQ (AMPH), Frankfurt (29A.F), München (29A.MU), Düsseldorf (29A.DU).
Amphastar Pharmaceuticals Inc. is a publicly traded company based in California, USA, specializing in the development, manufacturing, and marketing of injectable and inhalable pharmaceutical products. It was founded in 1996 and has built a wide range of products used in various therapy areas such as anesthesia, cardiology, emergency medicine, oncology, endocrinology, and neurology. The main business of Amphastar is the manufacturing and sale of injectable generic drugs used in hospitals and healthcare facilities. Some of the notable products include Ampicillin and Cefazolin, antibiotics used for treating infections. The company also produces anesthesia medications such as Lidocaine, Ketamine, and Midazolam, as well as adrenaline used for life-threatening allergic reactions. Another area of business for Amphastar is injectable Heparin products used for preventing blood clots. These products are sold under the brand names Amphastar and Nanjing Pharmaceutical. Amphastar also produces and distributes Naloxone hydrochloride injections used for opioid overdoses, as well as Enoxaparin injections used for preventing blood clots in patients after surgeries. In addition to injectable products, Amphastar has a pipeline of inhalable products in development, which offer promising growth opportunities. These products are specifically intended for treating respiratory diseases such as COPD and asthma. They are sold under the brand names Primatene Mist and Epinephrine. The company also has a division in the contract manufacturing of pharmaceutical active ingredients and raw materials, including analysis and quality control. Amphastar's customers primarily consist of other pharmaceutical companies that are unable or unwilling to manufacture certain products themselves. Amphastar primarily operates in the USA but also exports a significant portion of its products to Europe, Asia, and other parts of the world. The company has distribution partners in many countries and collaborates closely with distributors and wholesalers to distribute its products. Amphastar's business model is based on a combination of manufacturing its own products, contract manufacturing, and expanding its product portfolio through the development of inhalable products. The company emphasizes high quality and strict regulatory standards to gain the trust of its customers and investors. Amphastar has obtained international GMP standards, FDA approval, and numerous other certifications to ensure the quality and safety of its products. In summary, Amphastar Pharmaceuticals Inc. is a leading provider of injectable pharmaceuticals, also involved in the development of inhalable products. The company has fueled its growth through a combination of its own products and contract manufacturing and aims to expand its product portfolio to increase market share in the USA and internationally.
The expected revenue of Amphastar Pharmaceuticals is 747.81 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Amphastar Pharmaceuticals is 143.23 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Amphastar Pharmaceuticals is currently 8.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Amphastar Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Amphastar Pharmaceuticals is currently 1.70. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Amphastar Pharmaceuticals stock.
The Eulerpool Quality Score for Amphastar Pharmaceuticals is 6/10.
The ISIN of Amphastar Pharmaceuticals is US03209R1032. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Amphastar Pharmaceuticals is A11664. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Amphastar Pharmaceuticals is AMPH. The ticker symbol is used to trade Amphastar Pharmaceuticals shares on the stock exchange.
Amphastar Pharmaceuticals stock
Amphastar Pharmaceuticals Peer Group
Amphastar Pharmaceuticals Ticker
Amphastar Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Amphastar Pharmaceuticals
Our stock analysis for Amphastar Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amphastar Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.